Section Edited by Aude Chapuis, MD and Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapyCongwen Wang, Lewei He, Jing Peng, Chong Lu, Meng Zhang, Xingling Qi, Mingxing Zhang, Yumeng Wang
28 August 2024
NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumorsKensuke Nakagawara, Makoto Ando, Tanakorn Srirat, Setsuko Mise-Omata, Taeko Hayakawa, Minako Ito, Koichi Fukunaga, Akihiko Yoshimura
16 August 2024
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responsesLeesa Lertsumitkul, Melinda Iliopoulos, Stacie S Wang, Sarah J McArthur, Lisa M Ebert, Alexander J Davenport, Raelene Endersby, Jordan R Hansford, Katharine J Drummond, Ryan Cross, Misty R Jenkins
7 August 2024
EphA3 CAR T cells are effective against glioblastoma in preclinical modelsPaulo Martins, Rochelle C J D’Souza, Niclas Skarne, Lea Lekieffre, Shane Horsefield, Madusha Ranjankumar, Xiang Li, Thuy T Le, Fiona Smith, Corey Smith, Jacqueline Burrows, Bryan W Day, Rajiv Khanna
7 August 2024
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapyHaider Al-janabi, Katy Moyes, Richard Allen, Matthew Fisher, Mateus Crespo, Bora Gurel, Pasquale Rescigno, Johann de Bono, Harry Nunns, Christopher Bailey, Anna Junker-Jensen, Munitta Muthana, Wayne A Phillips, Helen B Pearson, Mary-Ellen TaplinSee the full list of authors
25 July 2024
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myelomaCharlotte L B M Korst, Chloe O’Neill, Wassilis S C Bruins, Meliha Cosovic, Inoka Twickler, Christie P M Verkleij, Diane Le Clerre, Maria Themeli, Isabelle Chion-Sotinel, Sonja Zweegman, Roman Galetto, Tuna Mutis, Niels W C J van de Donk
25 July 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob Hullsiek, Kate J Dixon, Sam Wang, Anders J Lindstedt, Ryan R Friess, Shee Kwan Phung, Tanya S Freedman, Martin Felices, Emily N Truckenbrod, Jianming Wu, Jeffrey S Miller, Bruce Walcheck
24 July 2024
Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcomaJessica A Lake, Elena Woods, Eric Hoffmeyer, Kristin L Schaller, Joselyn Cruz-Cruz, Joseph Fernandez, Dejene Tufa, Benjamin Kooiman, Spencer C Hall, Dallas Jones, Masanori Hayashi, Michael R Verneris
23 July 2024
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumorsDan Li, Tianyuzhou Liang, Laura E Hutchins, Alexandra A Wolfarth, Sara Ferrando-Martinez, Byung Ha Lee, Mitchell Ho
23 July 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumorsMartin Wermke, Tobias A W Holderried, Jason John Luke, Van K Morris, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Ignacio I Wistuba, Edwin R Parra, Mohammad B Hossain, Sandra Grund-Gröschke, Katrin Aslan, Arun Satelli, Anantha Marisetty, Swapna SatamSee the full list of authors
22 July 2024